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Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-
treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which
restores normal plasma glucose levels by stimulation of hepatic glucose production. This
counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic
concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism
mediated by stimulation of intra-islet somatostatin release. Insulin’s capacity to inhibit glu-
cagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-
secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliﬂozin
(an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted
somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of
these compounds in vivo antagonises insulin’s hypoglycaemic effect. We extend these data
to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered
as adjuncts to insulin in diabetes therapy.
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P lasma glucose is maintained by a tug-of-war between thehypoglycaemic effect of insulin and the hyperglycaemiceffect of glucagon. Under normal conditions, the plasma
glucose is maintained at ≈5 mM in man. The beneﬁts of good
glycaemic control in diabetic patients are well known: it prevents
or delays diabetic retinopathy, nephropathy and neuropathy1.
Two major forms of diabetes are recognised: type 1 (T1D) has a
young age of onset and results in loss of insulin-secreting β cells
and a lifetime requirement for insulin replacement therapy. Type
2 diabetes (T2D) largely affects older subjects and involves
impaired insulin secretion and/or action. In both forms of dia-
betes, the hyperglycaemic effects of insulin deﬁciency are aggra-
vated by hypersecretion of glucagon2. Therapy includes drugs to
stimulate insulin release but when this fails, insulin injections are
required. However, accurate administration of insulin to maintain
normoglycaemia is difﬁcult; too little will not regulate glucose and
too much exogenous insulin may produce hypoglycaemia.
Hypoglycaemia results in glucose deﬁciency in the brain, coma
and (if not alleviated) ultimately death. In normal situations,
hypoglycaemia would trigger a counter-regulatory response in the
α cells (stimulation of glucagon release and increased hepatic
glucose production) but this does not occur in many T1D and
some T2D patients3. Patients with T1D experience on average
two episodes of symptomatic hypoglycaemia every week4 and it
has been estimated that up to 10% of these patients die of
iatrogenic hypoglycaemia5. Thus, hypoglycaemia is ‘the limiting
factor in diabetes therapy’6 and, if it were not for hypoglycaemia,
diabetes could be easily managed simply by increasing the insulin
dose until normoglycaemia is restored.
Pancreatic islets are complex structures consisting of several
types of endocrine cell. In addition to the insulin-producing β
cells and glucagon-secreting α cells, islets also contain a small
number (5–10%) of somatostatin-secreting δ cells7. The regula-
tion of somatostatin release is complex and involves a crosstalk
between paracrine and intrinsic effects8. The δ cells are elec-
trically excitable and somatostatin secretion is associated with
increased action potential ﬁring involving activation of voltage-
gated Ca2+ channels. The increase in cytoplasmic Ca2+ resulting
from plasmalemmal Ca2+ entry is ampliﬁed by Ca2+-induced
Ca2+ release (CICR) from intracellular Ca2+ stores9. Somatos-
tatin is a paracrine inhibitor of both insulin and glucagon10–14.
Accumulating evidence suggests that increased somatostatin sig-
nalling, via suppression of glucagon secretion, results in the loss
of appropriate counter regulation during insulin-induced
hypoglycaemia15,16. However, the link (if any) between insulin
therapy and the loss of counter regulation remains obscure.
Here we have investigated the regulation of glucagon secretion
by insulin in mouse and human islets. We show that insulin
inhibits glucagon secretion by a paracrine effect mediated by
stimulation of somatostatin secretion rather than a direct effect
on the α cells. These ﬁndings highlight the importance of the
intra-islet paracrine crosstalk and suggest that therapeutically
targeting somatostatin secretion or action may restore counter-
regulatory glucagon secretion and thus minimise the risk of fatal
hypoglycaemia.
Results
Insulin stimulates somatostatin secretion. In preliminary
experiments, we found that insulin stimulates somatostatin
secretion in isolated pancreatic islets. We examined the glucose
dependence of insulin’s stimulatory effect on somatostatin
release. It was negligible at 1 mM glucose and limited to 50% at
10 mM glucose. However, at 4 mM glucose, insulin enhanced
somatostatin release by >200% (Fig. 1a). Insulin had no stimu-
latory effect when applied in the presence of 70 mM K+ (Fig. 1b),
a condition that depolarises the δ cells to −11 ± 1 mV (mean
value ± standard error of the mean of six experiments: not
shown), or when tested in the presence of 0.2 mM of the KATP
channel blocker tolbutamide (Fig. 1c), which initiates continuous
action potential ﬁring in δ cells17. The effects of insulin on
somatostatin release were not mimicked by insulin-like growth
factor 1 (IGF-1), resistant to the IGF-1 receptor antagonist
PQ40118 (Fig. 1d) but abolished in the presence of the insulin
receptor antagonist S961 (Fig. 1e). Collectively, these observations
suggest that insulin exerts its effect on somatostatin secretion by
binding to insulin receptors, is without stimulatory effect at low
glucose, exerts its greatest stimulatory effect at glucose con-
centrations slightly above the threshold for initiation of soma-
tostatin secretion, is ineffective when the KATP channels are fully
closed and requires a negative membrane potential.
Insulin’s glucagonostatic mediated by somatostatin. Somatos-
tatin is a powerful inhibitor of glucagon secretion10. We hypo-
thesised that insulin’s glucagonostatic action could be mediated
by somatostatin. We ﬁrst measured the effects of increasing
concentrations of insulin on glucagon and somatostatin release in
isolated mouse pancreatic islets exposed to 4 mM glucose
(Fig. 2a). Insulin inhibited glucagon secretion in a dose-
dependent manner (IC50 ≈100 pM) with nearly maximal inhibi-
tion at 300 pM. This was echoed by a concentration-dependent
stimulation of somatostatin secretion that was ﬁrst detectable at
300 pM of insulin and that did not saturate even at concentra-
tions as high as 0.3 μM. For comparison, plasma insulin levels in
non-diabetic individuals range between ~50 pM and 450 pM and
may be as high as 8 nM in insulin-treated type 1 diabetic
patients19.
We next examined whether the inhibitory effect of insulin on
glucagon secretion are mediated by somatostatin using the
somatostatin receptor (SSTR) antagonist CYN154806. In the
presence of 1 μM of CYN154806, the inhibitory effect of insulin
on glucagon secretion was abolished, whereas the stimulatory
effect on somatostatin secretion was unaffected (Fig. 2b, c). At the
concentration used, CYN154806 is expected to block both SSTR2
and SSTR320, the functionally important SSTRs in human21 and
mouse α cells22. CYN154806 also increased glucagon secretion
measured at 4 mM glucose by ~60%, an effect we attribute to the
relief from paracrine suppression by somatostatin released at this
glucose concentration.
No glucagonostatic effect of insulin in SIRKO mice. We tested
the systemic role of insulin-induced somatostatin release by
generating somatostatin-secreting δ-cell insulin receptor knock-
out (SIRKO) mice (Supplementary Fig. 2a, b). SIRKO mice were
normal weight and normoglycaemic (Supplementary Fig. 2c, d).
However, female SIRKO mice were much less insulin sensitive
than female control mice (Fig. 3a). No difference in insulin
sensitivity was detected between male control and SIRKO mice
(Fig. 3b).
Increasing glucose from 1 to 4 mM stimulated somatostatin
secretion and inhibited glucagon secretion in control and SIRKO
islets (Supplementary Fig. 3a, b). In control islets, insulin
(100 nM) stimulated somatostatin secretion by > 100% when
tested at 4 mM glucose but was without effect in SIRKO islets
(Fig. 3c). The loss of insulin-induced somatostatin release in
SIRKO islets correlated with the complete abrogation of insulin’s
glucagonostatic effect (Fig. 3d). We point out that the α cells in
SIRKO mice retain their insulin receptors. The failure of insulin
to affect glucagon secretion in SIRKO mice therefore suggests that
activation of insulin receptors in α cells does not directly inhibit
glucagon secretion. There were no differences between the effects
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of glucose or insulin on glucagon and somatostatin secretion in
isolated islets from male and female SIRKO mice (Supplementary
Fig. 3c-f). For this reason, hormone secretion data from male and
female mice were pooled. Thus, the differences observed between
male and female SIRKO mice in vivo are therefore likely to reﬂect
systemic rather than intra-islet mechanisms. Interestingly, the
counter-regulatory response also shows a sex difference in
humans23,24.
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Fig. 2 Insulin exerts its glucagonostatic effect by somatostatin. a Effects of increasing concentrations of insulin (3 pM, 30 pM, 300 pM, 3 nM, 30 nM,
300 nM; logarithmic abscissa) on glucagon (red) and somatostatin (black) secretion in the presence of 4 mM glucose (n= 10 experiments/6 male mice).
Arrow indicates IC50 for inhibitory effect of insulin on glucagon secretion (~100 pM). *p < 0.05, **p < 0.01 and ***p < 0.001 and †††p < 0.001 for the effects
of insulin on somatostatin and glucagon secretion vs 4mM glucose alone, respectively, one-way ANOVA followed by Dunnet’s post hoc test. b
Somatostatin secretion at 4 mM glucose in the absence and presence of insulin and/or CYN154806 (n= 10 experiments//6 male mice). ***p < 0.001 vs
4mM glucose; ††p < 0.005 vs 4mM glucose and CYN154806, one-way ANOVA followed by Dunnet’s post hoc test. c As in b but glucagon is measured
(n= 10 experiments/6 male mice). Secretion has been normalised to secretion rates at 4 mM glucose. *p < 0.05 and **p < 0.01 vs 4mM glucose; ††p <
0.005 vs 4mM glucose and insulin. Data are presented as dot plots of individual experiments and/or mean values ± S.E.M. of all experiments with the
experimental series
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Fig. 1 Insulin stimulates somatostatin secretion. a Somatostatin release at 1, 4 and 10mM glucose in the absence or presence of 100 nM insulin (n= 8–10
experiments using six male mice). †p < 0.05, †††p < 0.001 vs the same glucose concentration but in the absence of insulin, one-way ANOVA followed by
Dunnet’s post hoc test. Glucose (4 and 20mM) also stimulates somatostatin secretion compared with 1 mM in both the absence and presence of insulin
(p < 0.05 or better, not indicated for clarity). b, c Lack of effect of insulin on somatostatin secretion elicited by high [K+]o (70mM at 4mM glucose; b) and
by the KATP channel blocker tolbutamide (0.2 mM at 1 mM glucose; c). When [K+]o was increased, Na+ was correspondingly reduced to maintain iso-
osmolarity. **p < 0.01 vs 1 mM glucose alone (n= 10 experiments/5 male mice), one-way ANOVA followed by Dunnet’s post hoc test. d Effects of insulin
or IGF-1 on somatostatin secretion at 4mM glucose in the absence and presence of the IGF-1R inhibitor PQ401 (n= 10 experiments using six male mice).
***p < 0.001 vs control (no insulin); †††p < 0.001 vs control in the presence of PQ401, one-way ANOVA followed by Dunnet’s post hoc test. e Effects of
insulin and the insulin receptor antagonist S961 on somatostatin release in isolated mouse islets incubated at 4 mM glucose (n= 9 experiments/3 male
mice). ***p < 0.001 vs no insulin. †††p < 0.001 vs 100 nM insulin in the absence of S961, one-way ANOVA followed by Dunnet’s post hoc test. Responses
have been normalised to somatostatin secretion at 1 mM or 4mM glucose as indicated. Data are presented as dot plots of individual experiments and/or
mean values ± S.E.M. of all experiments with the experimental series
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Insulin increases [Ca2+]i in δ cells. Glucose-induced somatos-
tatin release is a Ca2+-dependent process that depends on CICR9.
We investigated the effect of insulin on δ-cell [Ca2+]i in islets
expressing the genetically encoded Ca2+ indicator GCaMP3
under the control of the somatostatin promoter. In islets exposed
to 4 mM glucose, ~50% of δ cells exhibited spontaneous [Ca2+]i
oscillations and application of insulin (100 nM) increased their
frequency. Examples from two representative cells are shown in
Fig. 4a. Insulin did not evoke [Ca2+]i oscillations in δ cells that
were not spontaneously active. Insulin increased the frequency
and amplitude of these oscillations by 40% and 80%, respectively
(Fig. 4b, c).
Despite increasing [Ca2+]i, insulin had no consistent effect on
δ-cell action potential ﬁring when tested at 4 mM glucose
(Supplementary Fig. 4a-c). Close inspection of the measurements
revealed that a small depolarisation (1–3 mV) was observed in
four of the seven experiments (~55%) but even in these cells there
was no consistent increase in action potential frequency. This
suggests that the stimulatory effects of insulin on [Ca2+]i
principally involves mobilisation of Ca2+ from intracellular
stores. Indeed, insulin-stimulated somatostatin secretion was
reduced in the presence of thapsigargin, an inhibitor of the Ca2+-
ATPase of the sarco/endoplasmic reticulum (SERCA) (Fig. 4d).
SGLT2-dependent stimulation of somatostatin secretion. It has
been reported that sodium-glucose co-tranporter-2 (SGLT2)
inhibitors stimulate glucagon secretion both in vitro and
in vivo25–29. We hypothesised that the stimulatory effect of
insulin on somatostatin secretion is mediated by SGLT2, which is
activated by insulin30, and that this suppresses glucagon secretion
by a paracrine effect. At the mRNA level, Sglt2/SGLT2 is
expressed at low levels in mouse δ cells22. Using immunocy-
tochemistry, we found that 58% and 33% of the somatostatin-
positive cells were also positive for SGLT2 in mouse and human
islet cell preparations, respectively. The corresponding values in
somatostatin-negative cells (mainly α or β cells) were 8% and 13%
(Supplementary Fig. 5).
We tested the functional role of SGLT2 in insulin-induced
somatostatin secretion (Fig. 5a). The stimulatory effect of insulin
was abolished when extracellular Na+ was reduced from the
normal 140 mM to 10 mM. Similar inhibitory effects were
produced by application of the SGLT2 inhibitor dapagliﬂozin at
0.1 and 12.5 μM (the lower concentration should be speciﬁc for
SGLT2, whereas the higher concentration will also inhibit
SGLT1). Notably, none of these procedures affected somatostatin
secretion at 4 mM glucose alone.
The inhibitory effects of Na+ omission and pharmacological
inhibition of SGLT2 on insulin-induced somatostatin secretion
correlated with the loss of insulin’s glucagonostatic effect.
Importantly, none of these experimental conditions affected
glucagon secretion in the absence of insulin (i.e., at 4 mM glucose
alone; Fig. 5b).
We performed insulin tolerance tests in the absence and
presence of dapagliﬂozin. Regardless of whether co-administered
with dapagliﬂozin or not, insulin reduced plasma glucose by
~60% (Fig. 5c). Despite the weak effect on plasma glucose levels,
dapagliﬂozin strongly stimulated glucagon secretion (Fig. 5d).
These experiments were performed in male mice but similar
effects were observed in female mice (Supplementary Fig. 6a-b).
We point out that only 5% of somatostatin in plasma is derived
from the pancreatic δ cells8 and most assays (including the one
we use) cannot distinguish between pancreatic islet- and
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gut-derived somatostatin. It was therefore not attempted to
correlate the increased plasma glucagon to plasma somatostatin.
To exclude the possibility that dapagliﬂozin acts by a direct
effect on the α cell, we tested the effects of this SGLT2 inhibitor in
SIRKO islets. Dapagliﬂozin only affected somatostatin and
glucagon secretion in control islets whereas it had no effect in
SIRKO islets (Supplementary Fig. 7a-b).
SGLT2-dependent δ-cell electrical activity. SGLT2 is electro-
genic (it co-transports Na+ and glucose with a stoichiometry of
1:1)31 and insulin-induced stimulation of its activity should
accordingly be expected to depolarise the cell. Indeed, when
dapagliﬂozin was applied in the simultaneous presence of 100 nM
insulin and 4 mM glucose, it repolarised three out of four δ cells
by an average of 3 ± 1 mV (n= 4; p < 0.05 by paired Student’s t-
test) and reduced action potential ﬁring from 0.5 ± 0.2 to 0.2 ±
0.1 Hz (p < 0.01 by paired Student’s t-test) (Fig. 5e). Application
of 19 mM of α-methyl-D-glucopyranoside (αMDG), a non-
metabolisable glucose analogue transported by SGLTs at 1 mM
glucose depolarised the δ cell by an average of 2 ± 1 mV (n= 5)
but did not initiate action potential ﬁring. Addition of insulin the
continued presence of αMDG resulted in a further depolarisation
of 4 ± 2 mV (n= 5; p= 0.05 by paired Student’s t-test) and
evoked action potential ﬁring in two of the cells (Fig. 5f). The
input resistance of δ cells exposed to 1 mM glucose averaged
3.2 ± 0.8 GΩ (n= 10). From Ohm’s law, we estimate that the
operation of SGLT2 in δ cells gives rise to a current as small as ~1
pA. The small amplitude of the SGLT2-dependent current is
consistent with the reported low mRNA expression of Slc5a222.
We monitored the increase in cytoplasmic Na+ ([Na+]i) that
should be associated with SGLT2-mediated glucose entry. When
insulin was applied in the presence of 19 mM αMDG, [Na+]i
increased in 40% of the δ cells (Supplementary Fig. 8a-b). These
may correspond to the δ cells that express SGLT2.
Insulin’s glucagonostatic effect enhanced in diabetes. We used
the perfused mouse pancreas preparation to explore the effects
of insulin on δ cells in the intact pancreas. Under these experi-
mental conditions, the pancreas is perfused in situ at the phy-
siological rate (0.25 ml/min) and direction. Surprisingly, insulin
(100 nM–10 μM) consistently failed to affect glucagon secretion
when tested in the perfused mouse pancreas (Fig. 6a).
The lack of effect of exogenous insulin on glucagon secretion in
the perfused pancreases contrasts to the strong inhibition seen in
superﬁcial islets and may indicate that glucagon secretion is
already maximally suppressed by endogenous insulin released
from neighbouring β cells. We tested this possibility by inclusion
of a high concentration (10 μM) of the insulin receptor antagonist
S961 in the perfusion medium. As shown in Fig. 6b, S961
increased glucagon secretion by ~50%.
Very different results from those obtained in wild-type mice
were obtained when insulin was tested in diabetic Fh1βKO mice.
These mice lack the Krebs cycle enzyme fumarase in their β cells
and develop age-dependent diabetes32. When severe hypergly-
caemia presents (at 9–12 weeks of age), pancreatic insulin content
is reduced by 97%. A clear inhibitory effect of insulin (>15%
measured 2–8 min after addition of insulin) was observed in ﬁve
out of seven in pancreases of hyperglycaemic Fh1βKO mice
(Fig. 6c) but in none of the ﬁve experiments performed on wild-
type mice (Fig. 6a; p < 0.03 by two-tailed Fisher’s exact test).
In intact islets, the inhibitory effects of insulin on glucagon
secretion are reversed by the SSTR2 antagonist CYN154806
(Fig. 2c). CYN154806 had a similar effect when applied in the
presence of insulin in perfused pancreases of diabetic Fh1βKO
mice (Fig. 6d). On average, glucagon secretion increased
by >100% in the presence of CYN154806. We acknowledge
that this stimulation produced by the SSTR2 antagonist may
not be restricted to a reversal of insulin’s glucagonostatic
effect but reﬂects an increase in basal glucagon secretion
(cf. Figure 2c).
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Insulin tolerance tests conﬁrmed that CYN154806 antagonised
the hypoglycaemic effect of insulin in vivo, especially in diabetic
Fh1βKO mice (compare Supplementary Fig. 9), an effect we
attribute to increased glucagon secretion.
Human islets. We ascertained that the effects of insulin on
somatostatin and glucagon secretion in mouse islets can be
extended to human islets. In a total of 10 human islet prepara-
tions, insulin applied at 4 mM glucose stimulated somatostatin
secretion by 100–200% (Fig. 7a, c, e) and inhibited glucagon
secretion by >70% (Fig. 7b, d, f).
As in mouse islets, insulin’s stimulatory effect on somatostatin
secretion was prevented by S961 (Fig. 7a) and dapagliﬂozin
(Fig. 7e), effects that correlated with the abrogation of its
glucagonostatic effect of insulin while not affecting glucagon
secretion at 4 mM glucose alone (Fig. 7b, f). The SSTR2
antagonist had no impact on insulin’s stimulatory effect on
somatostatin secretion but abolished the inhibitory effect on
glucagon secretion. Unlike what was seen in mouse islets,
CYN154806 did not affect glucagon secretion in islets exposed
to 4 mM glucose alone (Fig. 7d, compare with Fig. 2c).
Discussion
Here we show that insulin inhibits counter-regulatory glucagon
secretion by a paracrine effect mediated by SGLT2-dependent
stimulation of somatostatin release. Our data suggest that
reported stimulatory effects of dapagliﬂozin on glucagon secre-
tion in vivo25,26,29,33 and in vitro27,28 may reﬂect (at least in part)
reduced somatostatin release. Importantly, cell-speciﬁc ablation
of the insulin receptors in δ cells leads to the complete loss of
100–100–100–100–
[Na+]o (mM) 140 10 140 140
Dapagliflozin (mM) 0.1–– 12.5
Insuln (nM)
0
1
2
3
a
S
om
at
os
ta
tin
 s
ec
re
tio
n
(n
or
m
al
is
ed
 to
 4
 m
M
 g
lu
co
se
)
***
4
c
40
20
0
–20
–40
–60
–80M
em
br
an
e 
po
te
nt
ia
l (
m
V
)
5 min
12.5 μM dapagliflozine
0 15 30 45 60
0
40
80
120
Time (min)
B
lo
od
 g
lu
co
se
 (
%
 b
as
al
)
100
60
20 Control
Dapagliflozin
A
U
C
0-
60
(m
M
*h
)
–6
–4
–2
0
0.0
100–100–100–100–
[Na+]o (mM) 140 10 140 140
Dapagliflozin (mM) 0.1–– 12.5
Insuln (nM)
b
G
lu
ca
go
n 
se
cr
et
io
n
(n
or
m
al
is
ed
 to
 4
 m
M
 g
lu
co
se
)
0.5
1.0
1.5
2.0
2.5
*
d
f
40
20
0
–20
–40
–60
–80M
em
br
an
e 
po
te
nt
ia
l (
m
V
)
1 min
100 nM insulin
0 15 30 45
Time (min)
0
20
40
60
80
100
P
la
sm
a 
gl
uc
ag
on
 (
pM
)
Dapagliflozin
Control
A
U
C
0-
45
 (
pM
*h
)
0
20
40
60
*
Fig. 5 Insulin activates SGLT2 in δ cells. a, b Somatostatin (a) and glucagon secretion (b) at 4 mM glucose in the absence or presence of insulin at normal
or lowered (10mM) extracellular Na+ ([Na+]o) with or without dapagliﬂozin as indicated. Responses have been normalised to secretion at 4 mM glucose.
* p < 0.05, ***p < 0.001 vs 4 mM glucose alone; †p < 0.05, ††p < 0.05 †††p < 0.001 for comparisons with 4mM glucose under control conditions (black bar).
Data are based on 6–8 experiments using islets from three male mice). Statistical analyses were performed by one-way ANOVA followed by Dunnett’s
post hoc test. c, d Insulin tolerance test. Plasma glucose (c) and glucagon (d) concentrations following intraperitoneal (ip) injection of insulin (at t= 0; 0.5
U/kg) in male mice (age: 9 wks) followed by injection of dapagliﬂozin (10mg/kg, ip: red) or vehicle (5% DMSO in sterile PBS, ip; black). (see
Supplementary Fig. 5 for corresponding data in female mice). In c, d, insets summarise effects of dapagliﬂozin on plasma glucose and glucagon expressed
as the area under the curve (AUC) during the ﬁrst 45min. *p < 0.05 vs control (no dapagliﬂozin) by Student’s t-test (4 mice for each condition). e Effects
of the SGLT2 inhibitor dapagliﬂozin (12.5 μM) on δ-cell action potential ﬁring in the presence of 4mM glucose and 100 nM insulin. Dapagliﬂozin was
applied as indicated above the trace (representative of n= 4 δ cells in four islets from three mice of both sexes). f Effects of insulin in the presence of
19 mM of the non-metabolisable glucose analogue α-methyl-D-glucopyranoside (αMDG) on δ-cell action potential ﬁring (n= 5 cells from three mice of
both sexes). Red dotted line indicates membrane potential before addition of insulin. Data in a–d are presented as dot plots of individual experiments and/
or mean values ± S.E.M. of all experiments with the experimental series
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08193-8
6 NATURE COMMUNICATIONS |          (2019) 10:139 | https://doi.org/10.1038/s41467-018-08193-8 | www.nature.com/naturecommunications
insulin’s glucagonostatic effect and we conclude that binding of
insulin to the insulin receptors on α cells does not directly inhibit
glucagon secretion. From a pathophysiological viewpoint, it is of
interest that exogenous insulin only affected glucagon secretion in
the perfused pancreas when the experiments were conducted in
diabetic animals. Thus, in non-diabetic animals/individuals, the
effects of exogenous insulin on glucagon secretion are likely to be
mediated by the systemic changes in plasma glucose rather than
intra-islet effects of insulin. This may account for the unexpect-
edly mild phenotype of the α-cell-speciﬁc insulin receptor
knockout mouse34. Islet blood ﬂow has been reported to be from
β cells to the α/δ cells35. Given our ﬁndings, it is of interest that
exogenous insulin only inhibited glucagon secretion during ret-
rograde infusion but was without effect anterogradely36.
It may seem counterintuitive that insulin retains an inhibi-
tory effect in isolated islets (a preparation in which islet cir-
culation has been abolished) but is without effect in the
perfused pancreas (in which the islets remain vascularised).
However, it should be noted that although the interstitial
insulin concentration may increase to unphysiologically high
levels in the centre of the isolated islet, the α and δ cells prin-
cipally reside in the islet periphery in mice17 and they are thus
exposed to an extracellular medium that is (at least initially)
devoid of insulin. We acknowledge that in human islets, the α
and δ cells are scattered throughout the islets7 but the structure
is less dense than in mouse islets with the δ cells residing close
to cell-free areas37 (possibly corresponding to blood vessels).
These ﬁndings suggest that the effects of insulin on somatos-
tatin and glucagon secretion will be critically dependent on the
experimental conditions (islet isolation, incubation volume,
shaking, perfusion rate, etc.), potentially explaining why insulin
has previously variably been reported not to affect, stimulate or
even reduce somatostatin secretion8.
Based on our experimental data, we propose the following
model for insulin-induced stimulation of somatostatin secretion
(Fig. 8). The δ cell possesses two glucose-sensing mechanisms
that operate in parallel: one that depends on SGLT2 and one that
depends on closure of the KATP channels. An increase in glucose
leads to closure of the KATP channels, which produces membrane
depolarisation and initiation of action potential ﬁring in a way
similar to that documented in β cells38. The ﬁnding that the
SGLT2 inhibitor dapagliﬂozin is without effect on somatostatin
secretion at 4 mM glucose suggests that low glucose concentra-
tions produce little (if any) activation of the SGLT2s. This is in
agreement with the ﬁnding that SGLT2 transports glucose with
an afﬁnity of 5 mM31. The effects of insulin on glucagon and
somatostatin secretion (inhibitory and stimulatory, respectively)
were abolished when extracellular Na+ was lowered. Using the
SGLT-speciﬁc substrate αMDG, we show that insulin-induced
activation of SGLT2 results in an increase in intracellular Na+
([Na+]i). The operation of SGLT2 will also be associated with
glucose uptake but its contribution to the overall glucose uptake is
likely to be smaller compared with that mediated by GLUT1 and
GLUT3, which are expressed at much higher levels. Importantly,
the operation of SGLT2 is electrogenic. At low glucose (when
KATP channel activity is high), the small current (~1 pA) resulting
from insulin-induced operation of SGLT2 is too small to depo-
larise the δ cell and evoke electrical activity. Conversely, electrical
activity and CICR are already maximally activated at high glucose
and activation of SGLT2 will exert little additional effect. How-
ever, at 4 mM glucose, KATP channel activity is sufﬁciently
reduced for the small insulin-induced and SGLT2-dependent
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Fig. 6 Effects of insulin in the perfused mouse pancreas. a Glucagon secretion measured before and after addition of insulin using the perfused mouse
pancreas preparation. For these experiments, wild-type mice were used. In each experiment, glucagon secretion was normalised to that at 4 mM glucose
prior to the addition of insulin (100 nM in three experiments and 10 μM in two experiments: responses have been pooled for display; female mice were
used). b As in a but the insulin receptor antagonist S961 was used instead of insulin (n= 7 female mice). c As in a but experiments were performed in
hyperglycaemic/diabetic Fh1βKO mice and using insulin at a concentration of 100 nM (n= 8 mice of both sexes). In a-c, the black bars represent mean
glucagon secretion measured during the 6min preceding the addition of insulin or S961. d As in (c) but CYN154806 was included as indicated (n= 4
diabetic Fh1βKO mice of both sexes). Glucagon secretion has been normalised to that in the presence of CYN154806 (measured at steady-state, 4–8min
after the addition; t= 4–8min). The red and bars represent glucagon secretion in the presence of insulin alone and following the addition of CYN154806,
respectively. Statistical signiﬁcances were analysed by Student’s t-test. *p < 0.05. Data are presented as dot plots of individual experiments and/or mean
values ± S.E.M. of all experiments with the experimental series
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current to elicit δ-cell electrical activity with resultant stimulation
of Ca2+ inﬂux and stimulation of CICR. This model is consistent
with the observed glucose dependence of insulin’s stimulatory
effect on somatostatin secretion. It also explains why insulin does
not enhance somatostatin secretion evoked by tolbutamide or
high-K+ depolarisation.
Our ﬁndings suggest that agents that reduce somatostatin
action (SSTR antagonists) or secretion (SGLT2 inhibitors) might
be useful as adjuncts to insulin in diabetes therapy. By restoring
glucagon-mediated counter regulation, this would allow more
aggressive insulin therapy (and thus improved glycaemic control)
while minimising the risk of hypoglycaemia. SSTR antagonists
seem particularly interesting in this respect because our in vivo
data suggest that although SGLT2 inhibitors stimulate glucagon
secretion, their simultaneous inhibition of glucose reabsorption
dampens any hyperglycaemic actions mediated by stimulation of
glucagon secretion.
Methods
Ethics. All experiments were conducted in compliance with all relevant local
ethical regulations.
Animal experiments in the UK were conducted in accordance with the UK
Animals Scientiﬁc Procedures Act (1986) and University of Oxford ethical
guidelines and covered by a Home Ofﬁce License. Studies in Sweden were
performed after approval by the Regional Ethical Review Boards in Lund and
Gothenburg.
Human pancreatic islets were obtained with ethical approval and informed
consent from the Nordic Network for Islet Isolation (Uppsala, Sweden).
Experiments were performed in compliance with all relevant ethical regulations
and study protocols were approved by the Regional Ethical Review Board in Lund.
Animals. Unless otherwise indicated, the hormone secretion measurements were
performed using islets from female or male mice C57BL/6, 16–20 weeks of age and
weighing 25–30 g.
The insulin tolerance tests in Fig. 5c, d and Supplementary Fig. 2 were
performed on female or male C57Bl6 mice. The experiments in Fig. 3a, b were
performed on SIRKO and control mice (generated as described below). The
experiments in Supplementary Fig. 9 were performed in the non-diabetic control
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Fig. 7 Effects of insulin in human pancreatic islets. a, b Somatostatin (a) and glucagon secretion (b) at 4mM glucose in the absence and presence of insulin
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and diabetic Fh1βKO mice. These mice develop age-dependent progressive
diabetes at 9–11 weeks of age32.
The electrophysiology and Ca2+ imaging were performed using islets from male
and female mice expressing tandem-dimer red ﬂorescent protein (tdRFP, here
simply referred to as RFP) or GCaMP3 under the somatostatin promoter
(see Supplementary material in ref. 39), respectively.
The mice were kept at constant temperature (22 °C) and 12-h light/dark cycles.
They had free access to a standard chow diet (B&K) and water ad libitum.
Generation of SIRKO mice. To generate the δ-cell-speciﬁc insulin receptor
knockout mouse line (SIRKO), SST-Cre-RFP-GCaMP3 mice40 were crossed with
homozygous insulin receptor ﬂoxed mice (IRﬂ/ﬂ) (Jackson laboratory IRlox Stock
Number 006955; see ref. 41), which have loxP sites ﬂanking exon 4 of the insulin
receptor gene. In Cre-expressing tissues, exon 4 is excised from the insulin receptor
gene. If translation were to occur, a truncated protein of 308 amino acids of the N-
terminal residues of the insulin receptor α-subunit, lacking the high-afﬁnity
binding site, transmembrane domain and kinase domain would putatively be
produced41.
The ﬁrst-generation offspring of the SST-Cre-RFP-GCaMP3 and IRﬂ/ﬂ mating
produced SST-Cre mice heterozygous for the insulin receptor ﬂoxed allele (i.e.,
SST-Cre-IR+/−). Heterozygous SST-Cre-RFP-IR+/− were selected and were back-
crossed with IRﬂ/ﬂ mice to generate mice that were homozygous for deletion of the
insulin receptor speciﬁcally in somatostatin-expressing tissues (including the δ
cells). These are referred to as SIRKO mice (i.e., SST-Cre-RFP-IR−/−). It is
acknowledged that there are also somatostatin-producing cells in the brain, in
peripheral neurons and in the gastrointestinal tract and that insulin receptors will
also be ablated in these tissues.
Littermates, which did not express SST-Cre but were homozygous or
heterozygous for the ﬂoxed insulin receptor allele (IRﬂ/ﬂor IRﬂ/+), were used as
controls.
To conﬁrm knockout of the insulin receptor in δ cells, the deletion of exon 4 in
the RFP-positive fraction of δ cells (obtained by ﬂuorescence-activated cell
sorting (FACS)) was assessed by reverse transcription (RT)-PCR. To verify that no
unspeciﬁc recombination occurred in other insulin receptor-expressing tissues,
expression of the insulin receptor gene was assessed also in RFP-negative islets cells
and in the liver (as negative controls). To generate complementary DNA (cDNA),
~10 ng of total RNA (extracted from FAC-sorted RFP-positive islet cells, RFP-
negative islet cells and from the liver of each SIRKO mouse) was reverse
transcribed.
PCR from corresponding cDNA yielded an amplicon of 514 bp in the control
tissues and an amplicon of 365 bp (lacking exon 4) in the SST-Cre-expressing
(RFP-positive) cells of SIRKO mice. To verify that the 365-bp band corresponded
to the truncated transcript, whereas the 514-bp corresponded to the wild-type
copy, the fragments were cloned into a pGEM®-T Easy vector (Promega) and
sequenced.
Preparation of pancreatic islets. Mice were killed by cervical dislocation, the
pancreases quickly removed and islets isolated either by collagenase (Sigma) or
liberase (Roche) digestion.
Media. For historical and technical reasons, slightly different media were used for
the various experiments.
For the hormone secretion measurements, a Krebs Ringer bicarbonate buffer
composed of (mM) 120 NaCl, 3.6 (human) or 4.7 (mouse) KCl, 2.5 CaCl2, 1.2
KH2PO4, 1.2 MgSO4, 10 HEPES and 25 NaHCO3 (pH 7.4 with NaOH)
supplemented with 0.2% (weight/volume) bovine serum albumin (BSA) was used
(EC1).
During the Ca2+ imaging experiments, the islets were superfused with a buffer
consisting of (mM) 139 NaCl, 4.7 KCl, 0.5 MgSO4, 2.6 CaCl2, 5 HEPES (pH 7.40),
0.5 NaH2PO4 and 2 NaHCO3 (EC2).
In the membrane potential recordings, the extracellular contained (mM) 140
NaCl, 3.6 KCl, 0.5 MgSO4, 0.5 NaH2PO4, 2 NaHCO3, 5 HEPES, 1.5 CaCl2 (EC3).
The pipette solution contained (mM) 76 K2SO4, 10 NaCl, 10 KCl, 1 MgCl2, 5
HEPES (pH 7.35 with KOH) (IC1) and 60 μg/ml of the pore-forming antibiotic
amphotericin B.
The measurements of cytoplasmic Na+ were performed in a medium
containing (mM) 140 NaCl, 4.7 KCl, 2.6 CaCl2, 1.2 MgCl2, 1 NaH2PO4, 5
NaHCO3, 10 HEPES and glucose as indicated (pH 7.4, with NaOH) (EC4).
All media were supplemented with glucose as indicated.
Whenever Na+ was reduced, iso-osmolarity was maintained by adding an equal
amount of choline-Cl (Na+). The measured osmolality of the media ranged
between 310 and 315 mOsm.
IGF-1, the SSTR2 antagonist CYN154806 and the IGF-1 receptor antagonist
PQ401 were obtained from Tocris. All other chemicals were from Merck AG,
(Darmstadt, Germany) or Sigma (USA).
Hormone release measurements in mouse islets. In each secretion experiment,
groups of islets were pooled together and 12 size-matched islets from 4 to 6 mice
were preincubated for 30 min at 37 °C in 1 ml of EC1 gassed with 95/5% O2/CO2
and supplemented with 0.1% fatty acid-free bovine serum albumin, and 1 mM
glucose.
Na+
[Na+]i
[Ca2+]i
[Ca2+]i
[Ca2+]i
Glucose
SGLT2
KATP
channel
(low)Ca2+
channel
RyR
Depolarization
& action
potential
firing
(αMDG)
Insulin
ATP/ADP
Glucose metabolism
GLUT 1,3
Glucose
CICR
SST
SST
ψ
ψ
–
+
+
Fig. 8 Schematic summarising the effects of insulin in δ cells. Relationship between SGLT2-mediated glucose uptake and δ-cell electrical activity, Ca2+
entry, Ca2+-induced Ca2+ release (CICR) and somatostatin release. Insulin stimulates SGLT2 activity. The operation of SGLT2 is electrogenic Na+-
dependent glucose uptake mediated by SGLT2 gives rise to a small depolarising current and may (in some cells with sufﬁciently high SGLT2 expression
and/or low KATP channel activity) trigger electrical activity (action potential ﬁring). The associated increase in cytoplasmic Ca2+ ([Ca2+]i) leads to
intracellular Ca2+ mobilisation by activation of ryanodine receptors (RyRs) and Ca2+-induced Ca2+ release (CICR). In addition to SGLT2, the δ cells also
express the glucose transporters GLUT1 and GLUT3. Glucose uptake via these transporters accounts for 99% of glucose uptake. Metabolism of glucose
leads to KATP channel closure, membrane depolarisation, electrical activity and CICR
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After preincubation, the buffer was changed to a medium supplemented with
test agents, and the islets were incubated for 60 min. All incubations were
performed at 37 °C with gentle shaking (30 cycles/min).
Immediately after incubation, aliquots of the medium were removed for assay of
glucagon and somatostatin.
The radioimmunoassay kits for glucagon and somatostatin were from Millipore
(USA) and Eurodiagnostica (Malmö, Sweden), respectively.
The accuracy of the size matching was conﬁrmed by measurements of islet
hormone content in a few of the experiments. The coefﬁcient of variation was 24 ±
8% (mean ± S.D. for four experiments) for somatostatin and 27 ± 8% (n= 9) for
glucagon.
Perfused mouse pancreas. The mouse pancreas perfusion experiments were
performed as described previously42. Brieﬂy, the pancreas was perfused at the
physiological rate in the presence of 4 mM glucose.
Hormone release measurements in human islets. For experiments on human
islets, the islets had been cultured in CMRL 1066 (ICN Biomedicals, Costa Mesa,
CA) supplemented with 10 mM HEPES, 2 mM L-glutamine, 50 μg/ml gentamicin,
0.25 μg/ml fungizone (Gibco, BRL, Gaithersburg, MD), 20 μg/ml ciproﬂoxacin
(Bayer Healthcare, Leverkusen, Germany) and 10 mM nicotinamide at 37 °C (5%
CO2) for 1–5 days prior to the experiments. The glucose concentration of the
CMRL 1066 medium is 5 mM.
The incubations were carried out essentially as described for mouse islets above
and as reported previously37,43,44 using the same reagents and assays.
The accuracy of the size matching was conﬁrmed by measurements of islet
hormone content. The coefﬁcient of variation was 28 ± 12% (mean ± S.D. for 16
experiments) for somatostatin and 28 ± 8% (n= 16) for glucagon.
[Ca2+]i imaging. Confocal [Ca2+]i imaging in islets from SST-GCaMP3 mice was
conducted in EC2 essentially as previously reported42. GCaMP3 was excited at
488 nm, and ﬂuorescence emission recorded at 510–515 nm. The pinhole diameter
was kept constant, and frames of 256 × 256 pixels were taken every 1–3 s. Images
were acquired using ZenBlue software (Carl Zeiss).
Membrane potential recordings. Membrane potential recordings were performed
using EC3 and IC1 at 34 °C using the perforated-patch technique as described
previously45. Mouse δ cells were identiﬁed by the expression of tdRFP or GCaMP3.
Intracellular Na+ measurements. Time-lapse imaging of [Na+]i in dispersed
mouse islets was performed on a Zeiss Axiozoom.V16 microscope. Cells were pre-
loaded with 6 μM of Sodium Green (Molecular Probes) for 30 min at room tem-
perature and imaged at several locations simultaneously. Sodium Green was excited
at 490 nm and emission was collected at 515 nm, using a CCD camera. Time-lapse
images were collected every 60 s and the bath solution (EC4) was superfused at
60 μl/min and the temperature maintained at 34 °C. δ Cells were identiﬁed by the
RFP ﬂuorescence. Images were acquired using ZenBlue software (Carl Zeiss).
Flow cytometry of islet cells (FACS). Pancreatic islets from either SST-Cre-
GCaMP3, or SST-Cre-RFP, or SIRKO mice as described above were dissociated
into single cells by trypsin digestion and mechanical dissociation. Brieﬂy, following
isolation islets were incubated in 1 ml of trypsin (TrypLE, Gibco) at 37 °C for 5
min. Enzymatic digestion was stopped by adding 9 ml of RPMI-1640 medium
supplemented with 10% fetal serum albumin (FBS), 1% penicillin–streptomycin
and 5 mM glucose. The islets/islet fragments were centrifuged for 5 min at 400 g at
room temperature. The supernatant was removed, and the islet pellet was resus-
pended in 600 μl of RPMI-1640 supplemented with 2% FBS, 1%
penicillin–streptomycin and 10 mM glucose. The trypsin-treated islets were
mechanically dissociated into single cells by trituration and ﬁltered through a
30-μm ﬁlter to remove remaining clumps of cells.
Single cells were passed through a MoFlo Legacy (Beckman Coulter). Fractions
of GCaMP3- or RFP-positive cells were isolated by combining several narrow gates.
Forward and side scatter were used to isolate small cells and to exclude cell debris.
Cells were then gated on pulse width to exclude doublets or triplets. GCaMP3-
positive cells were excited with a 488 nm laser and the ﬂuorescent signal was
detected through a 530/40 nm bandpass ﬁlter (i.e., in the range 510–550 nm). RFP
was excited with the 488 nm laser and the ﬂuorescent signal was detected through a
580/30 nm bandpass ﬁlter (i.e., in the range 565–595 nm). GCaMP3- or RFP-
negative cells were collected in parallel (Supplementary Fig. 1).
Plasma glucose measurements and insulin tolerance tests. Fed blood glucose
levels (data point before fasting) were measured from a blood drop obtained by a
tail vein nick using the Accu-Chek Aviva (Roche Diagnostic). The mice were then
fasted for 3–4 h prior to the experiments. Fast-acting human insulin (Actrapid,
Novo Nordisk) was injected intraperitoneally at the indicated doses with a 25-
gauge needle at time zero. CYN154806 or dapagliﬂozin were injected intraper-
itoneally with insulin as indicated. In the control experiments, insulin was co-
injected with the solvent.
Tail vein blood glucose levels were monitored using a glucometer before and 15,
30, 45, 60 and 90 min after injection and samples for serum glucagon analysis
(Mercodia Glucagon ELISA, Uppsala, Sweden) were collected in some experiments.
The hypoglycaemic effect of insulin varies depending on the mouse strain, age
of the animals and the experimenter, which is why the hypoglycaemic effect of
insulin shows some variability. Any statistical analyses are based on animals of the
same age and strain and experiments conducted by the same person.
Immunocytochemistry. For immunocytochemistry, single cells were ﬁxed in 2.5%
paraformaldehyde and kept at 4 °C. On the day of the experiment, cells were
permeabilised with 0.1% Triton X-100 in phosphate-buffered saline (PBS) for 5
min at room temperature. Permeabilisation was followed by blocking of non-
speciﬁc binding with PBS containing 5% swine serum for 20 min. The cells were
then incubated overnight with anti-SGLT2 antibodies (1:75, Santa Cruz Sc-393350)
at 4 °C. On day 2, cells were incubated with mouse Alexa-488 Tyramide kit
(T20948, Molecular Probes) according to manufacturer’s instruction. Cells were
then incubated in primary antibodies anti-somatostatin (1:100, Millipore,
MAB354) for 1 h at room temperature, followed by secondary antibodies Alexa 568
anti-rat (1:500, A-11077, Invitrogen) for 30 min by the nuclear stain RedDot2
(1:200, 40061, Biotium) for 10 min at room temperature. Samples were visualised
with a Bio-Rad confocal microscope using appropriate lasers and ﬁlters.
Data analysis. The action potential frequency was analysed after exporting the
Pulse ﬁles as ASCII ﬁles and conversion into an axon binary ﬁle (using ABF File
Utility, v2.1.57, Synaptosoft Inc., Fort Lee, NJ). The recordings were then analysed
in Clampﬁt 9 (Molecular Devices, Sunnyvale, CA). A template was generated for
each individual experiment by averaging 10–20 action potentials from each
recording. Action potentials were then detected and analysed using the event
detection/template search function of Clampﬁt 9.
For the analysis of the Ca2+ imaging, the recordings were replayed off-line, and
regions of interest were selected and analysed using the Zeiss LSM510 and Zen Blck
software and Origin 8.5 (OriginLab Corporation, Northampton, MA, USA).
Fluorescence signals (F) have been normalised to initial ﬂuorescence (F0). The
frequencies were calculated as numbers of Ca2+ spikes divided by the duration of
each condition.
Unless otherwise indicated, data are given as mean values ± standard error of
the mean (S.E.M.) of the indicated number of experiments (n). In the histograms,
the data points for the individual experiments are shown. For clarity, only mean
values ± S.E.M. are presented in the graphs.
In the hormone secretion measurements, each group of 12 islets was counted as
an experiment (islets pooled from 3 to 8 different mice). Experiments were
normally performed on 2–3 different days with new media prepared for each day.
For hormone secretion measurements on human islets, each group of 12 islets
was counted as an experiment. Experiments were performed using islets from three
donors. For the studies described in Fig. 7, islets from a total of 10 different donors
were used.
Because the experiments have been performed over >10 years and by several
investigators, secretion has been normalised to basal (usually 4 mM glucose, unless
otherwise indicated).
In the electrophysiology, Ca2+ and Na+ imaging, each cell was counted as an
experiment but cells were taken from multiple islets and animals.
Statistical signiﬁcances were (unless otherwise stated) evaluated using Student’s
t-test or analysis of variance (ANOVA) followed by appropriate post hoc tests for
multiple comparisons.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the ﬁndings of this study are available
within the article and its Supplementary Information Files or from the corre-
sponding author on reasonable request. A reporting summary for this Article ﬁle is
available as a Supplementary Information ﬁle.
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